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Abstract: Depression and anxiety are major mental health problems in all parts of the world. These
illnesses are associated with a number of risk factors, including oxidative stress. Psychotropic drugs
of a chemical nature have demonstrated several side effects that elevated the impact of those illnesses.
Faced with this situation, natural products appear to be a promising alternative. The aim of this study
was to evaluate the anxiolytic and antidepressant effects of the Petroselinum sativum polyphenols
in vivo, as well as its correlated antioxidant properties in vitro. Anxiolytic activity of the extract
(50 and 100 mg/kg) was evaluated using the open field and the light-dark chamber tests, while
the antidepressant activity was evaluated using the forced swimming test. The antioxidant activity
of the extract was evaluated by the 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical test and the
FRAP (iron-reducing capacity) test. The phenolic extract showed very powerful anxiolytic and
antidepressant-like effects, especially at a dose of 100 mg/kg, decreasing the depressive behavior in
mice (decreased immobility time) and also the anxiolytic behavior (tendency for discovery in the
center and illuminated areas) better even than those of paroxetine and bromazepam (classic drugs)
concomitant with those results the extract also showed an important antioxidant capacity. These
preliminary results suggest that Petroselinum sativum exhibits anxiolytic and antidepressant potential
for use as a complement or independent phytomedicine to treat depression and anxiety.
Keywords: Petroselinum sativum; polyphenol; anxiolytic; antidepressant-like; antioxidant; pharmacol-
ogy; herbal medicine; natural products
1. Introduction
Depression and anxiety disorders have long been considered mental health issues,
and they constitute a heavy burden for any society in which stress is omnipresent. The
World Health Organization (WHO) predicts that by 2030, depression, as a potentially fatal
disease, will be the second leading cause of disability worldwide [1]. According to the
latest WHO estimates, more than 300 million people worldwide suffer from depression, of
which more than 260 million also have anxiety disorders [2].
The Diagnostic and Statistical Manual of Mental Disorders (DSM-V) defined major
depressive disorder as not just an occasional sadness or bout of depression, but rather a
depressed mood or loss of interest or pleasure for at least two consecutive weeks, episodes
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of which are often recurrent [3]. The WHO also defines depression as “a variety of psycho-
logical and biological symptoms, such as a general feeling of sadness, loss of pleasure and
interest, the feeling of guilt, disturbed sleep (insomnia or drowsiness) and appetite, feelings
of fatigue (psychomotor retardation), and lack of concentration”. In the most serious cases,
depression can even lead to suicide [4].
Anxiety, as defined by the WHO, is “a feeling of undetermined imminent danger
accompanied by a state of malaise, agitation, helplessness, or even annihilation”. It can
also be described as a state of anticipatory fear caused by potential and uncertain danger,
although its cause is not necessarily conscious, as opposed to fear that arises in the face
of real danger. However, these two emotions are characterized by similar physiological
(increased blood pressure, sweating, tachycardia, etc.) and behavioral (increased alertness
and avoidance) responses [5].
Depression and anxiety are generally treated with psychotropic medications, including
antidepressants and anxiolytics (tranquilizers), often chemical in nature, such as paroxetine
and benzodiazepines. However, the use of these medications exhibits certain limits, and
they may cause unwanted side effects. Bromazepam is prescribed for the treatment of
anxiety. However, its consumption comes with a number of negative side effects, including
drowsiness, sedation, and memory loss [6]. Difficulty sleeping, loss of appetite, drowsiness,
and sexual dysfunction are also typical side effects of paroxetine, an antidepressant from the
serotonin reuptake inhibitor (SSRI) family used to manage major depressive disorders [7].
As a result of this limited efficacy, the exploration of new, more effective, and non-toxic
therapeutic means is highly appreciated.
Medicinal plants can be an adequate source of new, safe, and effective therapeutics,
especially as many are known to exhibit fewer side effects [8]. Multiple medicinal plants
have been tested in the above disorders, and they yielded very pleasant results that
encouraged further studies to discover antidepressant-like and anxiolytic proprieties of
additional plants [9].
Petroselinum sativum Hoffm., commonly known as “parsley” (“maadnous” in Arabic),
is a member of the Apiaceae family. Apium crispum Mill, Apium petroselinum L., Petroselinum
hortense Hoffm and Petroselinum crispum (Mill) Fuss. are also synonyms for Petroselinum
sativum Hoffm. [10]. Parsley, as a culinary herb that originated from the Mediterranean
region, has become a globally common herb in modern times [11]. P. sativum has a range of
beneficial properties, including antioxidant, analgesic, spasmolytic, antidiabetic, immuno-
modulating, and gastrointestinal effects [12]. These various benefits may be attributed
to the plant’s core components, such as polyphenols (apigenin, quercetin, luteolin, and
kaempferol), vitamins, carotenoids, coumarin, and tannins [13]. The Apiaceae family
encompasses multiple plants known for their antidepressant and anxiolytic activities like
Coriandrum sativum L. [14], Pimpinella anisum L. [15], Carum carvi L. [16] for a concentration
ranging between 50 and 200 mg/kg.
In this study, potential antidepressant-like and anxiolytic activities of parsley polyphe-
nols were evaluated for the first time, along with its antioxidant activity, to determine
whether there was a correlation.
2. Results
2.1. Evaluation of the Antioxidant Activity
2.1.1. DPPH Test
Figure 1 shows the percentage of antioxidant activity as a function of different levels of
PSPE and BHTs. The results obtained reveal that our extract and BHT display concentration-
dependent antiradical activity. That is to say, the percentage of inhibition of the DPPH
radical increases with the concentration of the phenolic extract of P. sativum and BHT.
BHT showed the highest activity compared to our extract. For 0.5 µg/mL, BHT
reached a maximum inhibition percentage of 90%, which remained constant for a concen-
tration of 1 µg/mL. At the same concentration, the phenolic extract produced a maximum
inhibition of 58%.
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In order to compare the efficiency of the polyphenolic fraction of P. sativum (PSPE)
with that of BHT, we determined the concentration that reduced 50% of the FRAP (IC50).
BHT (The synthetic antioxidant BHT) showed highly potent antioxidant activity with
an IC50 of about 0.09 µg/mL, higher than that recorded for the phenolic extract of P. sativum
(about 0.38 µg/mL).
2.2. Evaluation of Antidepressant Activity
Forced Swimming Test
The variation in the downtime in the forced swimming test during the three weeks
of the experiment is shown in Figure 3. The immobility time during the test was signif-
icantly shorter in PSPE-treated mice (PSPE 50 mg/kg (34 s ± 3.286), PSPE 100 mg/kg
(33.8 s ± 2.653)) compared to controls (Paroxetine (100.8 s ± 6.837), Vehicle (176 s ± 6.550)).
These results show that the antidepressant effect of the phenolic extract of P. sativum
is greater than that of paroxetine.
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. . Evaluation of the Anxiolytic Activity
2.3.1. Anxious Behavior in the Open Field
Figure 4 shows the variation in he time spent at the cen er of th open-field test
duri g the three weeks of ext act tr atments. I can be seen that mice treated with PSPE
(50 and 100 mg/kg) sp nt m re time in the central ar a compared to the control groups.
This signific nt increase is proportional not only to the dur tion of tre tment but also to
the concentration of the extract. The optimal value was obtained with a concentration
of 100 mg/kg (37.4 s ± 1.778, compared to 33.4 s ± 1.208 sat a dose of 50 mg/kg). This
indicates an anxiolytic effect of this plant.
The variation in the number of tiles crossed during the three-week experiment is
shown in Figure 5. Analysis showed a remarkable increase in the number of tiles traversed
by PSPE-treated mice (50 mg/kg (161.2 ± 5.490), 100 mg/kg (173 ± 10.104)) compared
to the bromazepam 1 mg/kg (115.8 ± 1.393) and vehicle (147.4 ± 1.568)-treated groups.
These results indicate a greater anxiolytic effect of FPPS even than that of bromazepam at
1 mg/kg.
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3. Discussion
e demonstrated in this study that the phenolic extract of P. sativum displays antioxi-
dant activity in vitro and anxiolytic and antidepressant activities in vivo.
Ferulic acid and cinnamic acid have been found to have antidepressant effects in some
studies [17,18], while quercetin and hydroxytyrosol demonstrated an approved anxiolytic
effect [19,20]. Those compounds could be behin the observed effect.
e effecti e ess f a a ti i a t ca e e erte i iffere t f r s, s c as t e
s i f fr r i ls, t siti f fr r i ls, ls t l ti f
t l i [ ]. is ti it l t , t l tt f
, i , t i l t tr cts [ ].
et al. [21] showed that the aqueous extract of parsley xerted weak inhibitory
activity of the DPPH radical, w th an IC50 on the rder of 12.0 ± 0.10 mg/mL (co pared to
the polyphenolic extract in our study, 0.184 µg/mL). Conversely, the chelating effect of this
extract was more effective compared to other extracts used in the same study.
Recent studies also found a link between mood disorders and oxidative stress [22,23]
and psychological stress [24,25], thus opening new avenues preventing and/or managing
anxiety and depression regarding the potential application of antioxidants. Desrumaux
et al. [26] noticed that vitamin E deficit in mice’s brains raised levels of key signs of oxida-
tive stress and anxiety-provoking behaviors. Likewise, mice given vitamin C have recently
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revealed that this compound has an antidepressant role based on the tail suspension test
results [27]. Polyphenols, including flavonoids and phenolic acids, are well-known for their
potent antioxidant effects [28,29]. The usage of these secondary phytochemical metabolites
as a way of avoiding and managing anxiety and depression may be a promising strat-
egy [9]. A study carried out by Akinci et al. [30] demonstrated that parsley is successful in
minimizing stress-induced gastric damage when taken orally by supporting the antioxi-
dant defense system of cells, which is reflected in an increase in mean tissue glutathione
levels (53.31 ± 9.50) and the activities of superoxide dismutase (15.18 ± 1.05) and catalase
(16.68 ± 2.29).
The open-field experiment is used to evaluate an animal’s emotional condition. Ani-
mals who have been separated from their home cage and put in a different setting often
demonstrate distress and anxiety by presenting changes in all or some of the parameters,
like a decrease in ambulatory activity, exploration, and immobilization, but an increase
in grooming behavior [31]. P. sativum extract at a dose of 100 mg/kg produced a very
significant anxiolytic effect, as displayed by the significant increase in time spent at the
center of the field and total ambulatory activity. This increase was greater than that seen in
mice treated with bromazepam at 1 mg/kg.
The light-dark room experiment is also useful in predicting the anxiolytic effect of
medications. In order to measure the degree of anxiety in mice during this test, two
parameters are noted: (1) The lower percentage of time the animal spent in the dark
chamber is related to its anxiety level. In other words, when the percentage of time spent
in the lighted compartment is minimal, anxiety is deemed high, and (2) the number of
transitions, i.e., the number of passages between the two compartments, is inversely related
to the level of anxiety (lower number of transition means high anxiety level) [32]. The
findings of this study revealed P. sativum polyphenolic extract at 100 mg/kg showed an
optimal anxiolytic effect based on the animals’ increased time spent in the lighted chamber
and the number of transitions compared with controls during the study period.
The forced swimming experiment was developed in the 1970s. It is also known by the
name of its inventor as the Porsolt test [33]. Our finding indicates that the immobility time
of the treated mice was shorter than that of the control mice, indicating an antidepressant
effect of the phenolic extract of P. sativum. However, this decrease in the immobility time
may have been in favor of either an increase in swimming time or climbing time. This
difference is very important from a neuropharmacological point of view since theoretically,
during forced swimming, antidepressants producing a predominantly noradrenergic or
dopaminergic rise reduce immobility by increasing the time of escalation [34], whereas
those that activate 5HT instead reduce immobility by increasing swimming time [35]. In
terms of CNS function, the majority of polyphenols interact directly with neurotransmitter
systems [36]. Studies conducted on parsley show a predominance of flavonoids [37].
The broad variety of flavonoids found in conventional traditional medicinal extracts are
reported to have sedative/anxiolytic effects by direct binding to GABA A receptors [38].
A study carried out by Priprem et al. [39] indicates that the polyphenol quercetin
demonstrates anxiolytic activity after a week of repeated administration at the dose of
300 mg/kg, which is not as effective as diazepam, which exhibits its effect one hour after
administration at lower doses. Pereira et al. [40] showed that rosmarinic acid exhibits an
anxiolytic effect at very low doses (2 to 4 mg/kg). Another example is apigenin, which
demonstrates a selective and low affinity for benzodiazepine receptors producing an
anxiolytic activity with almost no side effects [41]. Flavonoids also play a role in depression
through inhibition of monoamine oxidase and the resulting increase in 5-HT, DA, and
norepinephrine levels in certain areas of the brain [42].
Excitatory amino acids, such as aspartate, glutamate, homocysteine, and cysteine, stim-
ulate post-synaptic cells, whereas inhibitory amino acids, such as alanine, glycine, GABA,
and taurine, suppress post-synaptic cell development [43]. An enzyme called aromatic
L-amino acid decarboxylase, also called DOPA decarboxylase, tryptophan decarboxylase,
5-hydroxytryptophan decarboxylase, or AAAD, which catalyzes the respective decarboxy-
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lation of L-dopa and 5-hydroxytryptophan into dopamine and 5-hydroxytryptamine may
also play a role. Parsley may cause overexpression of this enzyme, contributing to its
antidepressant effect. A study carried out on Centella asiatica, a plant belonging to the same
Apiaceae family, showed that the antidepressant effect of total triterpenes was due to the
improvement of the function of the hypothalamic-pituitary-adrenocortical axis and the
increase in the content of monoamino neurotransmitters [44]. These studies suggest the
presence of anxiolytic and antidepressant activity by the phenolic extract of P. sativum.
4. Materials and Methods
4.1. Plant Material
Petroselinum sativum Hoffm. aerial parts were collected during the pre-flowering
phase (spring 2018) from Tanounate region in North Morocco (34◦32′9′′ N 4◦38′24′′ W).
Classification, identification, and botanical name of this plant were verified by a qualified
botanist Pr. Bari Amina. The plant’s sample is deposited at the Faculty of Sciences Dhar El
Mahrez Fez herbarium (voucher specimen: 18TA5001).
4.2. Extraction
Extraction was carried out as described by Slighoua et al. [11]. Briefly, 10 g of the dried
aerial parts of P. sativum fine powder was mixed with methanol (100 mL) and macerated
for 3 h at a temperature of 50 ◦C. Afterwards, the filtrate was concentrated using a rotary
evaporator until dryness to ensure complete solvent evaporation. The resulted extract was
redissolved in distilled water (200 mL) and washed out with three hexane and chloroform
(200 mL three times) to get rid of the pigments and other impurities. The final aqueous
phase was extracted with ethyl acetate (200 mL three times). The organic phase (ethyl
acetate) was concentrated to obtain the polyphenol extract. The yield of the extraction
is 10.52%.
Our previously published work on the same extract demonstrated by using HPLC-
DAD analysis that it is composed of the following polyphenols: (1) Ferulic acid, (2) Cin-
namic acid, (3) Gallic acid, (4) Quercetin, (5) Myricetin, (6) Naringenin, (7) Hydrox-
ytirosol [11].
4.3. Study Animals
In this study, mice (Swiss albino) were provided by the Animal House of the faculty
of sciences Dhar el Mahraz Fez. Before being included in the experiments, they were put
in groups of six in conventional cages and were allowed a two-week adaptation period
with free access to food and water and a controlled temperature of 22 ± 2 ◦C and under a
light/dark cycle of 12 h/12 h.
Experiments were performed pursuant to international standards for the Treatment
and Use of Experimental Animals [16] and the Internal Animal Ethics Committee (#09-
12/2019/LBEAS).
4.4. Evaluation of the Antioxidant Activity
4.4.1. 2,2-Diphenyl-1-picrylhydrazyl (DPPH) Test
DPPH is one of the most common chemical compounds used for assessing the an-
tioxidant activity of phenolic compounds [45]. DPPH possesses an unpaired electron on
a bridge atom of nitrogen. The principle of this test is summarized in the capacity of the
extract to reduce the dark purple DPPH free radical into a yellowish-colored reduction
measurable by spectrophotometry [28]. A series of extract concentrations was prepared in
methanol, 100 µL of each of which was added to 750 µL of a methanolic solution of DPPH
(0.004%). After an incubation period of 30 min at 25 ◦C, the absorbance was measured at
517 nm. For the negative control, the sample was replaced by methanol. The percentage of
DPPH was determined by the following equation:
I = [(Blank − Sample)/Blank] × 100 (1)
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I is the percentage of antiradical activity, Sample is the absorbance of the sample, and
Blank is the absorbance of negative control.
4.4.2. Ferrous Reducing Power (FRAP) Test
The reducing power of iron (Fe3+) in the extract studied was determined according
to the method described by Mechchate et al. [28]. Briefly, 100 µL of the extract at different
concentrations was mixed with 500 µL of a phosphate-buffered solution (PBS, 0.2 M, pH 6.6)
and 500 µL of a 1% solution of potassium ferricyanide K3Fe(CN)6. These were incubated in
a water bath at 50 ◦C for 20 min. Then, 500 µL of a 10% aqueous solution of trichloroacetic
acid (TCA), 100 µL of a 0.1% solution of ferric chloride FeCl3, and 0.5 mL of distilled
water were added to the reaction mixture. The absorbance reading of this mixture was
taken at 700 nm against a blank containing all the reagents of the medium except the plant
extract. The results are expressed as 50% effective concentration (EC50), which represents
the concentration of antioxidants necessary to obtain an absorbance of 0.5. An increase in
absorbance corresponds to an increase in the reducing power of the extract tested.
4.5. Antidepressant Activity
Forced Swimming Test (FST)
The Porsolt model, or forced swimming test, is a predictive test of antidepressant-type
activity. Mice are individually forced to swim in a cylindrical container filled to the height
of 12 cm with water. The test lasts 6 min, but only the last 4 min of the test are analyzed.
The animal is considered immobile when it floats in an upright position and makes only a
few movements in order to maintain its balance in the water (immobility time).
A total of four batches of five mice each were used for this test. All plant extracts were
administered by gavage for 21 days, and the test was performed 1 h after the administration
of the extracts on 21 days. Group A, the negative control, received a physiological solution
as a vehicle. Group B, the positive control group, received paroxetine at 11 mg/kg. Groups
C and D received PSPE at 50 and 100 mg/kg, respectively.
One hour after plant extract administration, the immobility time was counted for
6 min. The first two minutes allowed the mouse to adapt to the stress, and then, the mouse
became tired and immobilized with time. The immobility time was counted in seconds,
and then, it was compared with the immobility time of mice in the positive control group
(paroxetine) for reference [33].
4.6. Anxiolytic Activity
4.6.1. Open Field
The open-field (OF) test is used to predict anxiolytic activity, as animals show a
high degree of avoidance of a central area relative to the periphery. It is also used as an
exploration and locomotion test. The area consisted of four wooden walls 40 cm high
arranged in an area of 50 × 50 cm, divided into 25 tiles of equal size marked by black lines.
A total of four batches of five mice each were used for this test. All plant extracts were
administered by gavage for 21 days. Next, the test was performed 1 h after the plant extract
administration on days 1, 7, 14, and Group A, the negative control, received a physiological
solution as a vehicle Group B, the positive control, received bromazepam at 1 mg/kg.
Groups C and D received PSPE at 50 and 100 mg/kg, respectively.
After 60 min, the test was performed by placing each mouse in the central square to
explore the arena to measure the total ambulatory activity of the mice (the number of total
tiles crossed by the mice, i.e., the number of peripheral tiles and the number of central
tiles crossed by the mice with all four legs) and the time spent in the center of the open
field [31,46].
4.6.2. Light-Dark Room Test
The light-dark room test is also used to predict anxiolytic activity, as it allows easy
evaluation of anxiety-related animal behaviors by analyzing the movements of the animal
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between two compartments of different color and illumination. More anxious animals
tend to spend less time in the lit room. The wooden light-dark box with dimensions
44 × 21 × 21 cm consisted of two black and white compartments, connected by a passage
(a hole of 7 × 7 cm in the center, separating the two compartments and allowing access to
one or the other of the compartments). The illuminated compartment was illuminated by
a lamp.
A total of four batches of five mice each were used for this test. All plant extracts
were administered by gavage for 21 days. The test was performed 1 h after the plant
extract administration on days 1, 7, 14, and 21. Group A, the negative control, received a
physiological solution as a vehicle. Group B, the positive control, received bromazepam at
1 mg/kg. Groups C and D received PSPE at 50 and 100 mg/kg, respectively.
After 60 min, the five-minute test was performed by placing each mouse facing the
opening joining the dark compartment [47]. After each test, the box was cleaned with
alcohol. The parameters measured were the time spent in the lighted chamber and the
number of chamber transitions [48].
5. Conclusions
Parsley, a daily used culinary herb worldwide, presents enormous health benefits
and through this study, it has been shown to have a remarkable antidepressant-like and
anxiolytic activity, even better than classic drugs, especially with the dose of 100 mg/kg. In
the search for an effective medicine with fewer or almost no side effect, this plant could
be a well-placed alternative. This work encourages its daily consumption as well as its
development to a well-established phytomedicine.
Further research is needed to complete this work, including the performance of other
behavioral tests with the same extract to confirm its efficacy. Thus, a bioguided fractionation
of the phenolic extract of P. sativum is planned to identify the key component responsible
for the observed anxiolytic and antidepressant-like activities and to determine their precise
mechanism of action.
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